# Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine

> **NCT02580396** · NA · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DEVICE:** CanADVICE+® (smart phone app)

## Key facts

- **NCT ID:** NCT02580396
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-16
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580396, "Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02580396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*